Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Rettig, Michael P  [Clear All Filters]
2015
Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, et al. [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther. 2015.
2018
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med. 2018.
2021
Rimando JC, Christopher MJ, Rettig MP, Dipersio JF. Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation. J Clin Oncol. 2021:JCO2001587.
Huselton E, Rettig MP, Campbell K, Cashen AF, Dipersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, et al. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021;110:106713.
Xiang J, Shi M, Fiala MA, Gao F, Rettig MP, Uy GL, Schroeder MA, Weilbaecher KN, Stockerl-Goldstein K, Mollah S, et al. Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Adv. 2021.
2022
Greenberg ZJ, Monlish D, Paracatu LChiquetto, Dong Q, Rettig MP, Roundy NDee, Gaballa R, Li W, Yang W, Luke CJ, et al. The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex- mediated quiescence. Blood. 2022.
2023
Ghobadi A, Foley NC, Cohen J, Rettig MP, Cashen AF, Gehrs LN, Christ S, Street E, Wallace N, Ritchey JK, et al. Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood Adv. 2023.
Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski SM, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, et al. Hematopoietic Stem Cell Mobilization for Allogeneic Stem Cell Transplantation by Motixafortide, a Novel CXCR4 Inhibitor. Blood Adv. 2023.
Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023.
2024
Cancilla D, Rettig MP, Karpova D, Thakellapalli H, Singh M, Meyers MJ, Ruminski PG, Christ S, Chendamarai E, Gao F, et al. Targeting CXCR4, VLA-4 and CXCR2 for Hematopoietic Stem Cell Mobilization. Blood Adv. 2024.